September 17, 2010
Webinar
On June 28, 2010, the U.S. Supreme Court issued its highly anticipated opinion in the landmark case Bilski v. Kappos. Bilski addresses what is perhaps the most fundamental question in patent law: what is patentable? At the Supreme Court, where Finnegan argued on behalf of inventors Bernard L. Bilski and Rand A. Warsaw, Bilski generated nearly 70 amicus briefs from parties ranging from Fortune 500 corporations to individual inventors. In its Bilski opinion, the Supreme Court agreed with Finnegan’s arguments that section 101 of the Patent Act should be interpreted broadly and that the Federal Circuit’s restrictive “machine-or-transformation” test should be rejected.
This webinar will examine the history and holding of this important case and also its implications for companies in Asia, both in litigation and at the U.S. Patent and Trademark Office. In particular, the webinar will offer:
• Impact and implications of Bilski for Asian companies
• Strategies for Asian companies to successfully protect and enforce (or attack) process patents in view of Bilski
• Should Asian companies continue to file and invest in U.S. patent applications for business methods?
• A view from counsel's table—first-hand recollections from a Finnegan attorney that represented Bilski and Warsaw at the Supreme Court
Moderator
Speakers
Time:
09/17, China & Taiwan (CST) 9:00 - 10:00
09/17, Japan (JST) 10:00 - 11:00
09/17, Korea (KST) 10:00 - 11:00
09/16, PDT 18:00 - 19:00
09/16, EDT 21:00 - 22:00
There is no charge to attend this program. Please register by September 14, 2010. Webinar access information will be sent upon registration.
Hybrid Conference
Intellectual Property Law Institute 2026 – California
October 19-20, 2026
San Francisco
Hybrid Conference
Intellectual Property Law Institute 2026 – New York
September 28-29, 2026
New York
Federal Circuit IP Blog
Federal Circuit Reinforces Injury-in-Fact Requirement in Appeals from Post-Grant Proceedings
June 10, 2026
European IP Blog
UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir
8 June 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.